Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin Plus Ketamine for Pain in Head and Neck Cancer
NCT05156060Phase 2Recruiting
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in acute pain and chronic pain. Primary endpoints: Maximum Tolerated Dose of Ketamine at 28 days and Count of participants with adverse events. Started Jan 2022; status: recruiting.
02
Drugs
ketamine
03
Conditions
acute painchronic pain
Beyond the preview
Go deeper on NCT05156060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156060.